Page 43 - Tannlegetidende 08-2020
P. 43

Krav til et klinisk brukbart munnskyllemiddel mot Coronavirus er at det ikke skader slimhinnene i det orale/nasopharyngeale områ- det og det har tilstrekkelig inaktiverende efekt på virus i løpet av en rimelig eksponeringstid som i praksis antagelig vil være 1 minutt.
Klorhexidin kan inaktivere forskjellige virustyper, men det er usikre data pga. ulike testmetoder som foreligger for virkning på Coronavirus.
Hydrogenperoksid som er tilgjengelig via apotek i Norge har vi- rusinaktiverende efekt på Coronavirus etter en rimelig klinisk kort eksponeringstid. En konsentrasjon på 3 % er bedre enn 1 % med hensyn til eksponeringstid og virkning. Mindre konsentrasjoner enn 3 % vil antagelig kreve lengre eksponeringstider.
Jodofor finnes i formuleringer som har virusinaktiverende efekt på Coronavirus etter en rimelig klinisk kort eksponeringstid, men
disse formuleringen er på nåværende tidspunkt ikke tilgjengelige som munnskyllemidler i Norge.
Anbefaling for munnskyll som er gitt fra de odontologiske fa- kulteter, Den norske tannlegeforening samt FHI må ansees å være fornuftige ut fra foreliggende viten og hvilke midler som var tilgjen- gelige i Norge når pandemien startet.
De foreliggende data for tilgjengelige munnskyllemidlers virk- ning på Coronavirus i den foreliggende pandemi er forbundet med usikkerhet pga. ulike testforhold. De viser at er et stort behov for forsking på efekt av og utvikling av klinisk anvendbare antiseptika med virusaktiverende efekt til bruk i det orale/nasopharyngeale området.
REFERANSER
1. Meng L, Hua F, Bian Z. Coronavirus disease 2019 (COVID-19): Emerging and future challenges for dental and oral medicine. J Dent Res. https://doi. org/10.1177/0022034520914246 (lest 12.4.2020)
2. Wang W-K, Chen S-Y, Liu I-J, Chen Y-C, Chen H-L, Yang C-F et al. Detection of SARS-associated Coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis. 2004; 10: 1213–19.
3. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G et al. Detection of SARS-CoV-2 in different types of clinical specimens. J Am Med Assoc. 2020; 323: 1843–44.
4. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B et al.. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microb Infect. 2020; 9: 386–9.
5. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L et al. Presumed Asymptomatic Carrier Transmission of COVID-19. J Am Med Assoc. 2020; 323: 1406–7.
6. To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C et al. Consistent detection of 2019 novel Coronavirus in saliva. Clin Infect Dis. ciaa149, https:// doi.org/10.1093/cid/ciaa149 (lest 12.4.2020)
7. European Commission. Directorate General for Health & Consumers. SCENHIR. Assessment of the Antibiotic Resistance Effects of Biocides. Adopted opinion 19 January 2009. https://ec.europa.eu/health/ph_risk/ committees/04_scenihr/docs/scenihr_o_021.pdf (lest 1.5.2020)
8. Regulation (EU). Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products. https://eur-lex.europa. eu/legal-content/EN/TXT/?uri=CE-
LEX %3A32012R0528 (lest 1.5.2020)
9. Ruppach H. Log10 reduction factors in viral clearance
studies. BioProcess J. 2014; 12: 24–30. http://dx.doi.
org/10.12665/J124.Ruppach (lest 12.4.2020).
10. Geller C, Varbanov M, Duval RE. Human Coronaviru-
ses: Insights into environmental resistance and Its Influence on the development of new antiseptic strat- egies. Viruses 2012; 4: 3044–68.
11. Committee for proprietary medicinal products (CPMP). Note for guidance for virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses. London 14 February, 1996 CPMP/BWP/268/95. https://www.ema.europa.eu/en/documents/ scientific-guideline/note-guidance-virus-validation- studies-design-contribution-interpretation-studies- validating_en.pdf (lest.19.4.2020).
12. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J et al. Epidemiology, genetic recombination, and pathogenesis of Coronaviruses. Trends Microbiol. 2016; 24: 490–502.
13. Ye Z-W, Yuan S, Yuen K-S, Fung S-Y, Chan C-P, Jin D-Y. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020; 16: 1686–97.
14. Liu DX, Yuan Q, Liao Y. Coronavirus envelope protein: A small membrane protein with multiple functions. Cell Mol Life Sci. 2007: 64: 2043–48.
15. Schoeman, D., Fielding, B.C. Coronavirus envelope protein: current knowledge. Virol J 16, 69 (2019). https://doi.org/10.1186/s12985-019-1182-0 (lest 12.4.2020)
16. Wolff M, Sattar SA, Adegbunrin O, Tetro J. Environmental survival and microbiocide inactivation of coronavirus. In: Coronavirus with special emphasis on first insights concerning SARS Eds. Schmidt A, Wolff MH, Weber O. Birkhäuser Advances in Infectious Diseases, Birkhäuser Verlag, Basel, Boston, Berlin, 2005, pp. 201–212.
17. Wisskirchen K, Lucifora J, Michler T, Protzer U. New pharmacological strategies to fight enveloped viruses. Trends Pharmacol Sci. 2014; 35: 470–78.
18. PRL. Pharmacal. Novel Coronavirus COVID-19. https:// www.pharmacal.com/COVID19.htm (lest 5.5.2020)
19. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen H-L, Chan MCW et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020; 1: E10.
20. Saknimit M, Inatsuki I, Sugiyama Y, Yagami K. Virucidal efcacy of physiochemical treatments against coronaviruses and parvoviruses of laboratory animals. Exp Anim. 1998; 37: 341–5.
21. Bruns P von. Ueber die behandlung inficerter Wunden mit Wasserstoffsuperoxyd. Berl Klin Wochenschr. 1900; 73: 405–6.
22. Handrick W, Stein H, Schmidt J, Ludewig R. Untersuchungen über die viruzide Wirkung von Wasserstoffperoxid. Z. ges. Hyg. 1969;15: 612–6.
23. Zolotarskaya EE, Dukhovnaya EM, Dreizin RS. Investigation of the possibilities of inactivation of adeno-associated type 4 virus (Oversatt fra russisk). Vopr. Virusol. 1975; 3: 341–4.
24. Wegener U, mentel R, Schmidt J. Die Anwendung von embryonalen Hühnertrachea-Organkulturen als Testmodell zur Prüfung antiviraler Substanzen gegen Influenzaviren. Zeitschr ges Hyg. 1975; 21: 688–90.
25. Mentel R, Shirrmacher R, Kewitsch A, Dreizin RS, Schmidt I. Virus inactivation with hydrogen peroxide (oversatt fra russisk).Vopr Virusol. 1977; 6: 731–3.
26. Kawana R, Kitamura T, Nakagomi O, Matsumoto I, Arita M, Yoshihara N et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatol. 1997; 195(suppl 2): 29–35.
27. Kumar KJ, Jayachandran E, Reddy CHK, Gunashakaran V, Ramesh Y, Babu PK et al. Application of broadspectrum antiseptic povidone iodine as powerful action: a review. J Pharmaceut Sci Technol. 2009; 1: 48–8.
28. Kariwa H, Fujii N, Takashima I. Inactivation of SARS Coronavirus by means of povidone-iodine, physical conditions, and chemical reagents. Dermatol. 2006; 212 Suppl 1: 119–23.
29. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efcacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018; 7: 249–59.
30. Eggers M, Eickmann M, Zorn J. Rapis and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome virus (MERS CoV) and modified vaccinia virus Ankara (MVA). Infect Dis Ther. 2015; 4:491–501.
31. Moskowitz H, Goodman J, Oral Health. Molecular iodine: could this be a game changer for dentistry? https://www.oralhealthgroup.com/features/ molecular-iodine-could-this-be-a-game-changer-for- dentistry/ (lest 5.4.2020)
 2020 · 130 · #8
625






















































   41   42   43   44   45